Astellas revisits gene therapy for XLMTM, offering new hope after earlier setbacks

A gene therapy for the rare muscle disorder X‑linked myotubular myopathy (XLMTM) showed mixed results in early trials, with some boys experiencing dramatic recoveries while others died.

Astellas Pharma is now re‑entering the field with a revised version of the therapy, aiming to address safety concerns and improve outcomes for patients.

The article follows the Gonzalez family, whose son Joshua survived the initial treatment and now breathes without constant suction, highlighting both the promise and the tragedy of the earlier approach.

The renewed effort underscores the ongoing challenges of developing gene therapies for rare diseases and could shape future research and investment decisions in the sector.